上記の広告は１ヶ月以上更新のないブログに表示されています。新しい記事を書く事で広告が消せます。

Dear 薏婷婷：


我看見了 妳/妳們 的關心，謝謝，很溫暖。
我需要休息，但我也有看見 妳/妳們 的緊張和焦慮..

這麼說好了，出國之前我也很緊張 (妳沒看過我剛來時剛接 long-term 的樣子，用這跟妳講可能比較容易些..) 研究所跟我感情最好的學妹 (不過很多時候我覺得她其實比較像我學姊.. ) 六月時跟我說了句很睿智的話：


"學姊，沒有關係。這樣妳可以沒有負擔的學習。在那兒妳會遇到很多很多人，大頭或許會邀請妳去他們實驗室.."


我很謝謝她這句真是有力量的安慰的話語。
我相信她，於是接下來我遇到了人一樣好的 Prof. Dr. Paul MacLean.

在那些個大家都質疑著我英文這麼差是要怎麼去 present 的日子裡，


Vivia,

Congratulations on the NHRI award!!

Do not worry about the language barrier- we will make sure it doesn't impair our interactions. And don't be intimidated by this group of scientists. They are just people, and they are just as excited about attending the conference. I am sure you will feel comfortable in and amongst the group once you begin interacting.

Best-

Paul


然後妳們都看到了，
"一段旅行，改變一個人的生活方式"，"教育，是一段生命影響生命的歷程。"



Dear 薏婷婷：


妳很好，相信妳自己。


"學長姐的功用是 生活關懷 / 工作協助 / 文化傳承。"

所以，我能做的我該做的、是幫助妳變得更好。即便是在國外，conference 上老師們給我的訓練，也是這樣。


妳不需要太擔心太害怕，妳已經處在一個世界級的很優秀的團隊裡頭，這是很重要的妳該認知到的事。890 的 data 發出去了，conference 上該看過的大頭們都看過了，那樣已經很好、就已經足夠。篩藥最重要的事情是快速和大量，這種事做久了自然會進步，只要用心 compound 篩多了自然可以看見差別和特點，永遠都沒有進步沒有心得那才是奇怪。


"小菜鳥就小菜鳥吧，這世界裡有著五年十年懂事以後完全不同的風景、再回不去的樂趣.."


一般的認知裡是覺得遇到這種 "大機會" 要表現得 "非常優秀" 才行，但越是這樣越容易 "凸槌"。
當妳遇過真正的大頭時，他們的態度會讓妳明白，基本上他們不要求新人要有多突出的表現，只要看到妳很認真想把一件事做好就好了。


妳就是妳，妳就是負責執行這件事的人，所以這件事是妳說了算、不是別人。
不需要管別人說什麼，他們不能說妳什麼不能對妳怎樣，妳只要做好該做的事就好。


Drug Discovery = Pharmacology + Toxicity

in vivo Pharmacology = evaluate compound efficacy & potency in animal model


我 ‧ 相 ‧ 信 ‧ 妳。


妳 seminar 要報的 paper 很棒。無論是 Dr. Philip Larsen 或 Dr. Alessandro Pocai，他們的 project 之所以成功，那都是他們的想法他們的 idea，而那些全都來自他們自身的經驗和 educational background。因為不 follow 別人，所以他們走得快也創新。


研究所的訓練給了小岩解決問題的能力，而生理所重視科學史的教法讓小岩耳濡目染銘記在心的是熟練技巧只夠完成工作，精通原理才能創新；

關於工作，那對小岩的人生意義、是能力的展現與實踐。那讓小岩看見了自己就算 26 歲嫁不出去也還不算太差太失敗，還是可以有夢想還是可以覺得自己不錯還是可以遇到很好的人還是會有很好很棒的事情發生。最最最重要的，是人在榮耀工作，而非工作榮耀人。請記住心理學家 Carol Tavis 這段話：

幸福並不藏在不必用心的享樂主義中，而是在需要用心的挑戰中；
幸福不在於擁有無限的機會，而在於聚焦了的可能性上面；
幸福不在於自我陷溺，而在於汲取世界的經驗；
不在於獲得了什麼，而在於完成了什麼。

不受考驗的生命也許不值得活，而沒有活過的生命也不值得檢驗。


這是之前寫給冠文的話，現在轉送給妳。

基本功做好 → 好好與小老鼠們相處，因為他們是妳的實驗 partner → 想法總是無可取代，用自己的方式、走出一條自己的路。


I do like Dr. Philip Larsen's guideline for me-

"Let your compound-treated animal reached the steady state (multiple-dose is necessary), then you can do anything you want. Everything can show the improvement about metabolic syndrome is OK. Try to let the compound mechanism story can mimic the natural physiological mechanisms, that's will be better."

Share this with you.


妳已經很好，我相信妳，請妳也相信妳自己。
我唯一對妳的要求和期許，是妳要開心、要在工作中有成長。

So happy could see blessing words from Dr. Alessandro Pocai!!!!!!
This is my best X'mas gift. Thanks a lot for Paul's kindly help.


Dear all:

Please keep fighting for our first industry-academia cooperation project, get true drug candidate.

Please believe me, United States is really an open country to us.



Wish Dr. Eric Yen could visit DBPR in Feb 2010.
He gave us a powerful help at IBMS, Academia Sinica in Oct 2009. I do believe he could give CB1 team members a solid faith, if he come.



"Vivia-
I am glad things are going well. It sounds like you are very happy."


Yes, I'm really very very happy. I appreciate you are such a kind-hearted chairperson, I appreciate your meaningful FASEB conference. Projects you handled are really amazing, I do believe you and Dr. Chao could become good friends, from you research!!!!! As I shown you some drug discovery opinions, as you all known I'm a rookie I'm just a RA, Dr. Chao is really an expert in drug discovery, I do believe opinions and suggestions from him are much more powerful and helpful than I can share with you. "From Bench to Beside", let's try together!!

I ‧ look ‧ forward ‧ that ‧ day ‧ you shake hand with Dr. Chao.



So happy my 2009 is AWESOME.
So happy things are going well and finally all have happy ending.


喜歡上一個未來要出國的女孩，很辛苦。
謝謝你一直最在意曬著煦煦陽光長大的我原本愛笑，謝謝你最在乎我要工作的開心、日子要過的快樂。

從台灣到美國，每個和善的老師們看著小妍、最後都會說，"妳，要開心。"


當決定步上紅毯，當責任義務未來都進到兩人關係之中，戀愛也不得不昇華為另一種更厚實的事業合作夥伴情感，支撐著現在、面對著將來，也從挫折中找到力量。

如同玩樂容易共事難，大家也說相愛容易同住難。婚姻的桎梏讓許多人只能默默消耗元氣、完全不知該如何解決應對。能夠為婚姻問題找到方法，讓雙方繼續走下去，需要溫暖需要幽默感還需要大手牽小手一直有人不放棄。

好的合作夥伴往往可以把人帶離自己的象牙塔小圈圈，而跨步踏出往往可以創造高收益。從愛情到工作，每一天，我都感謝自己成長了一點點。時間讓我不停地得到更多，讓我不是個什麼都不值的人，讓我有經驗有想法有能力解決問題而不害怕做決定。

我們從別人的眼光裡看見自己是個什麼樣的人： 他們想要聽我說話嗎？他們想要跟我工作嗎？他們想要跟我生活嗎？他們想要愛我嗎？他們想要得到我的愛嗎？

這些問題，我們在眼神相遇的那一刻都有答案。開始工作時小妍的名字只是個踏出校門等待未來的年輕小女孩、沒有人會在乎。但是總有一天，她的存在會有更大意義、會影響更多人，除了擔心她挨餓受凍感冒胃痛的父母，還會有其他人在乎。她會是某些人眼中的小公主，也會是其他人眼中望之生畏的母后，而這些那些又怎單純地僅止於與皺紋胸部皮膚有關聯？

我還是喜歡當公主不喜歡當女王。
只不過，現在學會了被遺棄時更應該堅強。

----------------------------------------------- -- Re：公主力？女王力？--



謝謝十年前小嘉學長帶我進 CDPA，然後我遇到了你、跟著你們一起生活一起玩耍一起在人生和感情路上成長；
十年後到美國參加研討會, 運氣很好地再度變成那個物種多樣性裡的 rare animal..

傻不隆咚 / 滿腦袋問號 / 大家都在笑的 "that girl，from Taiwan", 但還是同十年前那般活得平安喜樂, 每天開開心心有說有笑, 回來還能繼續跟人家保持互動提供貢獻..

謝謝那些花心思照顧小妍的老師們，謝謝你們努力做到 do not worry about the language-barrier.


原先參加 EB2010 時可以選擇 American Society for Pharmacology & Experimental Therapeutics，老師們覺得這樣比較好。決定是 APS 的那當下、能理解的人可能只有主席先生和他老師..


I still believe Physiology could be very powerful in drug discovery.

"如果你的背景會強到讓教授拿來當聊天話題 那也不用擔心 一般來說教授收這種信都會收到幾十幾百封" ← 我想，我終究是幸運到不行，因為大家都對我那麼好。

這幾天天冷，縮在爸爸新拿來的羽絨被窩裡靜靜讀完吳淡如 租來的人生 ─


這個世界或許只是一個超大型的租車公司；被命運善待的人，不過是向一家服務妥貼的租車公司租到了一部好車子。

不久前，到日本看櫻花，為了尋找自然風景，我租了車旅行。

日本的租車公司令人不得不誇讚。車一來，油加滿，目的地都有衛星導航，只要輸入電話，再複雜的路也暢行無阻。又是油電車，十分省油，停車時悄然無聲，公路修築完善，一路上半點顛簸感也沒有，連找停車場都有詳細指示。

還車時，服務員還會對我甜美微笑。

完美得有點悵然，真捨不得還。

這或許也只是完美人生的縮影。旅程的最盡頭，即使有些不捨，卻還是得往前行，再美妙的陪伴都帶不走。越順遂的人生，時光流逝得越令人心驚。

不像是租來的東西，都只是些抽象的東西而已。如過程、情感與記憶，都是屬於自己的獨特經歷。卻有許多人，對租來的東西十分盡心，對不是租來的東西十分粗心。

雖然說，是非成敗轉頭空，古今多少事，都已煙消雲散，就算是抽象的東西，也只對自己有意義，無法真正留下什麼，總會成為過去。但一輩子，談不好感情，受不了挫折，存不了美好記憶，還車前連一點值得咀嚼幾分鐘的旅程經驗也沒有，才是最讓人遺憾的事情。

租來的人生，值得斤斤計較或細細呵護的，唯有時間、唯有情。


這就是人生。

或許今天的一切，到了明早可能面目全非; 也可能這一刻的惶然無措, 下一分鐘卻迎刃而解。在這樣的未知裡, 我們能期待什麼？或許什麼也做不到，所以才更應該珍惜這當下每一分每一秒的小小幸福不是？

幸福不是平平安安沒有挫折，而是面對挫折或風暴時你的心態與眼光。

這是上帝給我們最大的禮物 ─ 學到我們還有那麼多地方，可以更好。


回頭看著已經超過百封的 e-mail，那些八月底九月初時看起來有些可笑還滿愚蠢的 "錯誤"，四個月後一切看來都好、很令人興奮，約好的大家 2012 再見提前到嘿能不能 2010 就見..


Happiness is very simple, so easy access to very pure talent.

四、建立台灣品牌，提升國際能見度

[...] 在與國外大廠訪談時，對於台灣的研究能力，甚少持正面肯定的態度，顯示我國在這方面仍有努力空間。我國雖然每年都派員參加研討會，但應該更積極重視發表與會議參與度，不只是學術上�疱�見聞與學習，也應推廣展示，提高台灣國際能見度。[...]

................................................................ -- 我國生醫產業如何掌握轉譯醫學之新興機會


我現在開始了解這是為什麼了。

我不想跟這個人這個計劃這間實驗室再有任何關係！


今天的電子報寫的是怎麼一回事？

我離開的 "官方理由" 不是 "計劃到期" 嗎？
我當初帶出去的不是 "這發不了 paper，拿去貼張 poster 也好" 的東西嗎？

結果主席先生為了這樣的垃圾 data 還跟藥廠大頭對戰，pharmacotherapy session 結束後變成學界和藥界兩邊對立，醫界公衛界各自選邊站.. 最後我還得自己去找 Dr. Philip Larsen 和 Dr. Alessandro Pocai 道歉，還好趕在最後一天大家恢復一團和氣、因為 Dr. Alessandro Pocai 不只研究做得好還真的是個和善的超級大好人，是他在 conference 結束時親自走去跟主席先生握手釋出善意的.

What's your contribution in this project？

不是說篩藥是 low-level 的工作、這都是垃圾等級的 data，發不了 paper。所以我們要改做 high-level 的 CB1 knockout mice 分子調控機制研究、那才有意義嗎？那天大吵一架的結果理所當然又是我輸，當天晚上嘉瑜快 12 點時不得不來實驗室陪我把做到一半的 TG sample 收完，免得我氣瘋了直接屁股拍拍包袱款款然後走人..

Project meeting 上說著一切 well-control 的話就怎樣怎樣..
當初讓這件事 well-control 的人都要走光了，妳自己連細節怎麼回事都忘記了，實驗室裡還記著的有誰？會記著的就會在乎，會在乎就止不住心痛，而妳是為了什麼一邊罵著斥責著已然心碎的我們又還繼續想讓這些 well-control？一個連 data 都不知道怎麼解釋 reference 不曉得從哪兒找來的人，為什麼敢說事情可以繼續 well-control？ 當初妳可是要求我要擔保我們家技術夠成熟到可以去篩藥！現在誰擔保？繼續找人來問我這怎麼做那怎麼做嗎？問完之後又到處跟別人介紹說這是誰誰誰的貢獻到處讓別人掛名嗎？


Conference remiander Dr. Sam Klein 問了我：

"Why your supervisor let you go here alone? they don't worry?"



What's ‧ your ‧ contribution ‧ in ‧ this ‧ project？

What's ‧ your ‧ contribution ‧ in ‧ energy expenditure study？



Shit!! 然後 oral review 那天莫名其妙的被修理和有苦說不出的被羞辱又再次浮上心頭。

套用那天我被釘著下不來而妳保持著殘忍的沉默的問話，


那張照片， 是 ‧ 誰 ‧ 拍 ‧ 的？ 妳要講啊，至少口頭上要提一聲啊..


修理 RA 大家都很在行，都認為是理所當然。那為什麼同樣的標準不適用於 PI？
Idea 誰的 / 誰是 true executor / 什麼樣的人有資格可以成為 project presentor / 做到什麼程度可以申請計劃展延，學術這條路上 PI 們不都走得更長久，不都應該更清楚？


[節錄自 http://seacity2.blogspot.com/2002/06/blog-post.html ]

C. Preliminary studies/progress report 初步研究／後續進展報告：
前面兩部分是空口說白話講得冠冕堂皇，這一部份就必須提出一些實證支持自己所提議的研究計劃是做得到的，絕非天馬行空胡思亂想的鬼點子。所以要列出自己已經完成哪些初步的實驗觀察、獲得哪些結果，以證實所提出的假說是有憑有據、設計的實驗方法確實可行。如果是後續展延的計劃，則要列出來在之前的計劃期間完成了哪些實驗目標，發表了那些期刊論文，顯示自己有能力也有信譽可以繼續深入的後續研究。換句話說，這裡要證明的是自己不是光會吹牛罷了，而是確已建立完備的實驗體系，有能力也有信用，符合資格來實際完成研究。（證據在此，錢不會白白浪費亂花掉的，放心地給吧！）

D. Research design and methods 實驗設計與方法：
研究計劃本文的最後一部份，也是最佔篇幅的實體核心部分，就是要仔細說明實驗會怎麼做。通常就是根據開頭提出的特定主旨，一項一項列出來：要如何實際去動手實作，會用到哪些技術，要怎麼設實驗組與控制組，有什麼可能的困難瓶頸，要與誰合作，資料要怎麼分析。如果原來所設想的實驗做不出來，又有哪些替代的方法可以實行。所以審查者可以清楚地知道你想用怎樣的材料與方法，可以評估這些方法與實驗設計有沒有辦法回答想問的問題，可以知道你有沒有忽略的盲點，還可以知道有沒有考慮好遇到問題時該怎麼辦。總之，除了說明自己到底要利用怎樣的實驗設計來達成所設定的目標，以完成所提議的特定主旨之外，也要顯示自己思慮周密瞻前顧後，大大小小都已考慮周詳，絕對不是走一步算一步地且戰且走。（所以構想完善萬事俱備只欠東風，經費快快通過撥過來哪！）


丟臉不要丟到國外去，人家都已經看見問題了，而且 conference 上還有出身台灣待過中研院的老師！"那不像 RA 的生活，就算在中研院的 RA 也不是這樣。妳已經很接近 PI 的世界了。" 當初不就自己在那兒說 Research Day 上哪個 PI 實驗室抱走一大堆獎是因為人家有錢煦當靠山，那麼，這資訊奉還給妳： FASEB 第一屆主席也是錢先生，人家還也是 APS 的會員。


這到底是個什麼樣的地方？為什麼可以容忍這樣的事情一而再再而三發生？
我就算是奉了意旨官小的走路，看著我的 CV 看著我的 awards，interview 的時候也沒人要相信我的理由是計劃到期所以需要離開!!!!!!

"如果妳的推薦人是這些人，那妳和妳老闆妳們兩個到底在幹嘛？妳們組到底怎麼一回事？"


Shit!!!!!!

BIT Life Sciences' 8th Annual Congress of International Drug Discovery Science and Technology (IDDST). Oct 23-26, 2010, Beijing, China.

→ [David Ko] Taiwan Site 你該長進了

→→ TED: John Wooden – The Difference Between Success and Winning
"It's you and I who make our fates, We open up or close the gates On the ROAD AHEAD or the ROAD BEHIND."

→→→ [ptt studyabroad :: 申請美國博班的路上還有我] We are the World.
Not for the degree, but for that I'm really wanting to work with them. They do believe compound is a good tool for research. They do believe research means hope, not only means publication. They do believe Science need collaboration, but not competition.

→→→→ Triacylglycerol systhesis and energy metabolism: a gut reaction? Clin. Lipidol. (2009) 4(6), 683-686

"Inhibiting MGAT2 appears to invoke a novel mechanism that increase energy expenditure rather than targeting appetite or fat digestion. However, many questions need to be addressed. For example, unlike mice, human also have MGAT3 expressed in the distal intestine. Can MGAT3 compensate for MGAT2 and possibly dampen the therapeutic efficacy of MGAT2 inhibitors?"

Ahh~ so happy could see this. I'm really really very excited to see these words!!!!!!
Next time I'll become a true project presenter, do the oral presentation to you all big names by myself.





如果驕傲沒被現實大海　冷冷拍下　又怎會懂得　要多努力　才走得到遠方
如果夢想不曾墜落懸崖　千鈞一髮　又怎會曉得　執著的人　擁有隱形翅膀

把眼淚種在心上　會開出勇敢的花　可以在疲憊的時光　閉上眼睛聞到一種芬芳
就像好好睡了一夜　直到天亮　又能邊走著　邊哼著歌　用輕快的步伐

沮喪時　總會明顯感到孤獨的重量　多渴望懂得的人　給些溫暖借個肩膀
很高興　一路上　我們的默契那麼長　穿過風　又繞了彎　心還連著　像往常一樣

最初的夢想　緊握在手上　最想要去的地方　怎麼能在半路就返航
最初的夢想　絕對會到達　實現了真的渴望　才能夠算到過了天堂


老師，很高興 conference 上有你，很高興你還跑回中研院幫我們的忙。

我的新 project leader 對我說 "很高興有機會認識妳，我們一起加油。"
老師，我們也一起加油！

我們就會回到最初的時光。





Dear dear 人小瑞：


一直想寫那個關於 "Systems Biology" 的信給妳。


科學是種高度內心思考辯證的活動。
從九月到現在，一直在寫 meeting report，一直在看 paper 一直在思考一直在重寫，一直在 "以為自己懂了" 和 "喔我想我還是不懂" 之間進行簡諧運動，一遍又一遍地發現著 conference 上的大頭和大大頭為什麼值得拍手稱讚景仰尊敬，

為什麼，這 session 是挑這些人來演講？
他們做了什麼傑出的貢獻，所以他們成為 invited speaker？


進度很緩慢，心情很愉快。
儘管一遍又一遍地發現自己跟大頭之間的巨大差異，人家 lecture 聽完馬上能用簡短地話語點出最重要的價值和貢獻；自己出國前要先研究過人家的背景、讀好人家的 publications，conference 時早早起床預習當天講課 speaker 的 abstract，運氣真好人家講完還會有大大頭幫忙給 comment 抓重點，回來還是中文的報告寫過一遍、讀更多 paper、再想再寫再改再讀再重寫，終於有辦法了解人家第一時間就給出的那句 comment 究竟多麼有價值而不只是筆記抄下來喔這人的貢獻是這樣..

但至少走到這一步，就已經可以看見自己的成長。


於是開始會思考，為什麼 2009 年主軸在 Physiological Basic 、2012 年卻是 Systems Biology？為什麼大頭們會相信會認為這樣比較好？除了那是潮流那是趨勢那是 founding policy 之外，讓他們真心相信這是有意義有價值很重要的研討會主軸的理由、是什麼？




昨天寫完 ghrelin with midbrain dopaminergic reward circuitry，然後看到這篇..
A Predictive Phosphorylation Signature of Lung Cancer (published in the journal PLoSone.)

"Since the signatures identify proteins and pathways where phosphorylation should be inhibited, the methodology highlights potential new targets for drug discovery."

"It is to be hoped that research on the neurobiology of feeding will contribute to a solution to the obesity epidemic."

"Future investigations of how metabolic signals affect motivational behavior will be informed by the vast literature on mesolimbic dopamine and the neurobiology of addiction, which may result in common targets for therapeutic intervention."


→ Systems biology. Nature Reviews Drug Discovery 8, 173 (February 2009)

The past decade in drug discovery has been dominated by a target-focused approach in which molecules are sought that specifically affect a particular protein with a link to disease. However, there has been growing appreciation of the limitations of this approach and a concomitant increase in interest in strategies that could allow more effective therapeutic intervention based on a systems-oriented understanding of disease biology and drug response.

Among the companies that focus on such strategies is e-Therapeutics, founded by systems biology researcher Malcolm Young in 2001."The core technical capability is an ability to evaluate the impact that a molecule will have on any cell for which we have data, on the basis of the set of proteins for which it has affinity — not just affinity for a single protein target," he explains. "If the cell is pathogenic or pathological we can gain insight into efficacy, and if the cell is a normal one, we can gain insight into safety and tolerance."

Young's laboratory, initially at the University of Oxford, and then at the University of Newcastle, UK, began developing approaches to understanding complex biological networks in 1991, and focused on applying these tools to investigate the organization of the brain."The core attraction to me of informatics and systems-level approaches is that, in my experience, they give much better insight into the systems being studied than reductionist approaches," he says.

By 2000, this neuroinformatics approach had matured to the extent that it was possible to successfully predict from network data where particular types of physiological function would occur in the brain. An unexpected visit from a pharmaceutical researcher shortly after publication of this research then provided the stimulus for the foundation of e-Therapeutics."The suggestion was that if we could predict the effects of multiple interventions on complex brain networks, then we should be able to do the same for macromolecular interaction networks in cells, and in that way develop a drug discovery platform," recalls Young.

Successfully realizing this goal has presented a range of challenges. "First, we had to build large protein-interaction and chemoproteomics databases from multiple, often inconsistent and always differently formatted sources, which we were able to successfully validate retrospectively by 2004," Young says. "But having a platform that predicts drug efficacy and safety much better than chance still doesn't constitute a business, and it took some time to work out where the best commercial opportunities for this capability lay."

In this respect, the company has focused on applying its technology to reposition drugs for specific premium clinical niches. "Accurate assessment of efficacy and safety can be applied to reposition compounds, rapidly, at low cost, and these candidates can often leap straight into Phase II trials," says Young. Several such compounds are now progressing in Phase II clinical trials."At the outset, I had the ambition that the company might help make just one patient better. The most rewarding feature so far has been the fact that our drugs have now done this for patients in multiple clinical settings," he concludes.


→→ BIT Life Sciences' 8th Annual Congress of International Drug Discovery Science and Technology (IDDST). Oct 23-26, 2010, Beijing, China.

Section 3-3: Diabetes & Other Metabolic Diseases


嗯，他們都還是很努力很樂觀地 From Bench to Beside: Development of a Drug to treat Obesity 吧！ 等 meeting report 全部寫完的那天，我想我可以跟妳講更多更深刻的、關於我們寫 SOP 的東西。


[The American Physiological Society] At the ACDP meeting, Tucson. Stephen Katz, NIAMS Director talked about their Programs & NIH. Started by saying "genome is well and good, but if you don't know physiological consequences...". Definitely resonated with the group.

Puhahahahahaha~ I ‧ do ‧ like ‧ APS!!!!!!

今天去跟新同事 say hello，原來大家都已經認識了嘛哈哈哈~


I do believe every "meeting" has its own meaning.
CC tell me my major task is conditioned place preference (CPP) study.


Dr. Jeffrey Zigman
Overriding energy homeostasis: The influence of central ghrelin systems

Using CPP and operant conditioning behavioral tasks, we demonstrate an obligatory role for ghrelin in certain rewarding aspecs of eating that is separate from eating associated with body weight homeostasis and that requires the presence of intact orexin signaling.


It's really... nice to meet you all.

"I am going to try to make it to EB this year, too. If we all end up going, we should have dinner some evening- I can meet your friends and we can catch up on the progress of your research there."


I look forward to listening your story in EB2010.
I look forward to seeing your contribution in CB1/ECS filed.

The true reason I finally decided to go back to graduate school, that's because of Eric's presention at IBMS, Academia Sinica. Hear my opinion in his presentation.. that's fully surprised me and really give me a shock-

you ‧ all ‧ recognize ‧ my ‧ contribution !!!!!


Thank you also do this for me.

As I told you previously Chia-Yu is my best friend at our lab, he asked me if I have any chance discuss his study to you or some other big names at conference free time, at the first day I back to Lab after the FASEB conference..

I'm really appreciate what you and Eric did for me. Although CCK is no longer the direction and major factor in your stories, I'm still grateful things you do for me. I can undersand CCK maybe the correct direction after I listened Dr. Nori Geary's lecture, thus I told you it's really too late to meet you all..


"一無所有的時候，我們才更珍惜無價的感情。"

One important thing Mark has taught me is just keep going then one day finally everything will become worthy.


I look forward to having a reunion with you in EB.
I'll try my best to give you a true "progress report" in Apr 2010. How I'm wanting that I could talk about metabolism, about your research, with you.

好高興喔.. 今天一個下午居然有三個人 跑來 / 打電話來 說要介紹新工作給小岩。能認識你們能跟你們一起做過事真是太好太開心了......

"Relationship is a mirror in which you can see yourself, not as you would wish to be, but as you are."

晚上小岩爸又帶著一串外婆家來的芭蕉給晚餐吃太飽正在對著 powerpoint 杜咕的小岩..

溫暖又感動滿滿的一天。


小岩會回到 RA = 唸書 + 玩耍 / 實驗室歡樂 / 伙伴們互相加油打氣彼此鼓舞的世界，一定會。Sales 朋友已經說了，新 Lab 笑聲多、挺快樂的啊！去圖書館領書的時候也看到好多好多新課本..

So happy~


I'm also happy about I can have Prof. Dr. Paul MacLean such an ideal mentor.

He remind me my happy imprint of APS and the Laboratory of Physiology at Harvard Medical School when I'm still a college student. He demonstrates that tradition and innovation can develop side by side in harmony.